Cervical Screening within HIV Care: Findings from an HIV-Positive Cohort in Ukraine

Heather Bailey1, Claire Thorne1*, Igor Semenenko2, Ruslan Malyuta2, Rostislav Tereschenko3, Irina Adeyanova4, Elena Kulakovskaya5, Lyudmila Ostrovskaya6, Liliana Kvasha7, Mario Cortina-Borja1, Claire L. Townsend1

1 MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, University College London, London, United Kingdom, 2 Perinatal Prevention of AIDS Initiative, Odessa, Ukraine, 3 Odessa Regional Centre for HIV/AIDS, Odessa, Ukraine, 4 Kiev City Centre for HIV/AIDS, Kiev, Ukraine, 5 Donetsk Regional Centre for HIV/AIDS, Donetsk, Ukraine, 6 Mykolaiv Regional Centre for HIV/AIDS, Mykolaiv, Ukraine, 7 Kriviy Rig City Centre for HIV/AIDS, Krivy Rig, Ukraine

Abstract

Introduction: HIV-positive women have an increased risk of invasive cervical cancer but cytologic screening is effective in reducing incidence. Little is known about cervical screening coverage or the prevalence of abnormal cytology among HIV-positive women in Ukraine, which has the most severe HIV epidemic in Europe.

Methods: Poisson regression models were fitted to data from 1120 women enrolled at three sites of the Ukraine Cohort Study of HIV-infected Childbearing Women to investigate factors associated with receiving cervical screening as part of HIV care. All women had been diagnosed as HIV-positive before or during their most recent pregnancy. Prevalence of cervical abnormalities (high/low grade squamous intraepithelial lesions) among women who had been screened was estimated, and associated factors explored.

Results: Overall, 30% (337/1120) of women had received a cervical screening test as part of HIV care at study enrolment (median 10 months postpartum), a third (115/334) of whom had been tested >12 months previously. In adjusted analyses, women diagnosed as HIV-positive during (vs before) their most recent pregnancy were significantly less likely to have a screening test reported, on adjusting for other potential risk factors (adjusted prevalence ratio (APR) 0.62, 95% CI 0.51–0.75 p<0.01 for 1st/2nd trimester diagnosis and APR 0.42, 95% CI 0.28–0.63 p<0.01 for 3rd trimester/intrapartum diagnosis). Among those with a cervical screening result reported at any time (including follow-up), 21% (68/325) had a finding of cervical abnormality. In adjusted analyses, Herpes simplex virus 2 seropositivity and a recent diagnosis of bacterial vaginosis were associated with an increased risk of abnormal cervical cytology (APR 1.83 95% CI 1.07–3.11 and APR 3.49 95% CI 2.11–5.76 respectively).

Conclusions: In this high risk population, cervical screening coverage as part of HIV care was low and could be improved by an organised cervical screening programme for HIV-positive women. Bacterial vaginosis testing and treatment may reduce vulnerability to cervical abnormalities.

Citation: Bailey H, Thorne C, Semenenko I, Malyuta R, Tereschenko R, et al. (2012) Cervical Screening within HIV Care: Findings from an HIV-Positive Cohort in Ukraine. PLoS ONE 7(4): e34706. doi:10.1371/journal.pone.0034706

Editor: Jianming Tang, University of Alabama at Birmingham, United States of America

Received December 13, 2011; Accepted March 5, 2012; Published April 24, 2012

Copyright: © 2012 Bailey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: HB is supported by a Medical Research Council (MRC) Doctoral Training Account Ph.D. Studentship. CLT is funded by the WellChild Trust through a research training Fellowship. CT holds a Wellcome Trust Research Career Development Fellowship (grant number 081082) which supports the postnatal cohort. The ECS has previously received funding from the European Union FP6 (PENTA/ECS018865) and receives funding from the EU Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement nº 260964. Some of this work was undertaken at GOSH/UCL Institute of Child Health which received a proportion of funding from the UK Department of Health’s NIHR Biomedical Research Centres funding scheme. The Centre for Paediatric Epidemiology and Biostatistics also benefits from funding support from the MRC in its capacity as the MRC Centre of Epidemiology for Child Health (grant number G0400546). The funders have no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: CT is a PLoS ONE Editorial Board Member. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: claire.thorne@ucl.ac.uk

Introduction

Ukraine has the highest adult HIV prevalence in Europe, estimated at 1.6% in 2007 [1]. Heterosexual transmission has now overtaken injecting drug use (IDU) as the main mode of HIV acquisition [2], and women account for almost half of those living with HIV in Ukraine [3]. HIV-positive women are at increased risk of acquisition and/or persistence or reactivation of cervical infection with Human papillomavirus (HPV) [4–6]. This is due to shared risk factors for acquisition (e.g. multiple sexual partners) and immunosuppression [7,8]. Cervical abnormalities in HIV-positive women are more likely to be severe, aggressive and resistant to treatment [9,10], and HIV-positive women have a 5 to 8-fold increased risk of invasive cervical cancer compared with the general population [11,12].

Regular cytologic screening can effectively reduce the incidence of invasive cervical cancer by up to 80% on a population level [13,14]. A two to three year screening interval is recommended by British and US guidelines for HIV negative women of childbearing age.
age [15,16], with more frequent (at least annual) screening for HIV-positive women, given their increased risk of morbidity [17,18]. Screening during pregnancy is not recommended by UK guidelines [15] because invasive cervical cancer in pregnant women is very uncommon, and treatment for less severe abnormality must be deferred until after delivery [19]. However, antenatal screening may be justified for HIV-positive women given their increased cancer risk. Perinatal care can also be an opportunity to engage marginalised women, who are unlikely to attend for screening at another time, and those who have previously defaulted on follow-up appointments for abnormalities [15]. However, cytologic samples taken during pregnancy (and up to 12 weeks postpartum) may be more difficult to interpret than samples taken at other times [20].

In Ukraine, cervical screening is recommended six-monthly for all women of childbearing age [21]. It is available free of charge at public health clinics, but is predominantly opportunistic. National policy includes a low-level recommendation (expert opinion) for screening as part of antenatal care, but there are no figures on coverage in this group or nationally [22]. World Health Survey data suggest that coverage with at least three-yearly screening in the general population is similar in Ukraine to many other European countries [23]. However, it is unclear whether this is the case among HIV positive women, who are more likely to be socially excluded [1] and require more intensive surveillance. Age-standardised mortality rates for cervical cancer are two-fold higher in Eastern than in Western Europe (7.1 vs 3.4 per 100,000) [24] and little is known about the prevalence of abnormal cervical cytology among HIV-positive women living in Eastern Europe.

We aimed to explore coverage of cervical screening as part of HIV care in a cohort of HIV-positive childbearing women in Ukraine receiving care at HIV/AIDS Centres, and to identify factors associated with an abnormal finding.

Methods

The Ukraine Cohort Study of HIV-infected Childbearing Women (“Women’s Cohort”) is an ongoing study established in December 2007. HIV-infected women who had recently given birth (usually within the last 12 months) and were receiving care at one of five participating regional HIV/AIDS Centres in Ukraine (situated in Odessa, Donetsk, Kiev, Kriviy Rig and Mykolaiv) were enrolled with informed consent [25]. This postnatal cohort is nested within the European Collaborative Study (ECS), a birth cohort study in which pregnant HIV-infected women in ten European countries are enrolled, and their infants prospectively followed according to a standard protocol [26]. The Ukraine ECS has been enrolling women since 2000 [27] and around 80% of women in the postnatal study were also in the ECS, allowing linkage across the two studies (both collect coded anonymised data with unique identifiers).

Maternal socio-demographic information was collected as part of the ECS (clinician-completed questionnaire) and at enrolment in the Women’s Cohort (woman-completed questionnaire). Clinical information, including data on cervical screening, was provided by the clinician at enrolment and thereafter when a woman returned to the HIV/AIDS Centre for care. Data collection was opportunistic and dependent on routine clinical visits; according to policy, clinical visits should be at least three monthly for women on ART and six-monthly for those not on treatment, but in practice follow-up intervals could be much longer. All clinicians providing care at the HIV/AIDS Centres were gynaecologists. Only information on screening tests received as part of HIV care was available to them and reported in this study.

Definitions

Results of cervical cytology were reported according to the 2001 Bethesda System as negative for intraepithelial lesion or malignancy (‘normal’), low-grade squamous intraepithelial lesion (LSIL) (corresponding to HPV infection, mild dysplasia or cervical intraepithelial neoplasia (CIN) 1) and high-grade squamous intraepithelial lesion (HSIL) (corresponding to moderate and severe dysplasia, carcinoma in situ or CIN 2 and CIN 3) [20]. A finding of LSIL or HSIL was defined as an abnormal result.

History of IDU was classified by self-report, clinical assessment or abstinence syndrome in the neonate. HIV clinical status was defined according to the World Health Organization (WHO) clinical staging criteria (advanced and severe symptomatic HIV disease corresponding to WHO stages 3 and 4 [29]). Previous pregnancy was defined as a previous live birth, stillbirth, miscarriage or termination, and multiparity as ≥1 previous live or stillbirth. Age at enrolment was categorised approximately into quartiles (16–23, 24–26, 27–30 and ≥31 years). Affordability of contraception was based on self-report.

Genital infections diagnosed with the following methods during the most recent pregnancy or postnatally (up to date of enrolment) were reported: bacterial vaginosis (BV) by Gram stain microscopy in 99% and by symptoms in 1%; vulvo-vaginal candida by Gram stain microscopy in 77%, culture in 14% and symptoms in 10%; Chlamydia Trachomatis (‘chlamydia’) by enzyme immunoassay on endocervical swab; Trichomonas vaginalis (TV) by microscopy.

Data Analysis

Of the five centres participating in the study, analyses were limited to Odessa, Kiev and Donetsk, as Kriviy Rig and Mykolaiv did not report any cervical screening.

The $\chi^2$ and Fisher’s exact tests for categorical variables were used to investigate univariable comparisons. Univariable and multivariable Poisson regression models with a robust variance estimate were fitted to estimate unadjusted and adjusted prevalence ratios (PRs and APRs) of having a cervical screening test reported at postnatal study enrolment, and of an abnormal finding (LSIL or HSIL). The models for having a test reported were fitted including all women and also restricted to those diagnosed prior to conception of their most recent pregnancy. The PRs and APRs thus estimated provide a more interpretable measure of effect than those resulting from odds ratios obtained with logistic regression models, which may be inflated where outcomes are common, and control for under-dispersion and confounding which depends on the measure of effect [30]. Explanatory variables investigated included socio-demographic factors (age, parity, educational status), health behaviours (alcohol use, smoking, IDU, contraceptive use, disclosure of HIV status), clinical status (WHO stage, CD4 count), use of postnatal ART, time since HIV diagnosis and self-reported affordability of contraception and coinfection with viral hepatitis. Study centre and year of enrolment (December 2007–08, 2009, 2010–11) were included as a priori in the multivariable analyses of factors associated with having a test reported to account for differences in local policy and changing clinical practice over time. Variables which remained significantly associated with the outcome after these adjustments (Wald test $p<0.1$) were included in the multivariable models. In analyses of factors associated with an abnormal finding, all variables known to be associated with invasive cervical cancer and available in our dataset were included a priori in the models (use of oral hormonal contraception, smoking, parity, Herpes...
| Table 1. Cohort characteristics by cervical screening test report. |
|---------------------------------------------------------------|
| **Median age at enrolment (IQR)**                          | Test reported at enrolment (n=337) | No test at enrolment (n=783) |
| 28.0 (25.2, 31.3)                                           | 27.0 (23.7, 30.2)                  |
| **Marital status (n=1113)**                                 |                                   |                              |
| Married                                                     | 225 (67%)                         | 412 (53%)                    |
| Cohabiting                                                  | 73 (22%)                          | 235 (30%)                    |
| Single\textsuperscript{1}/widowed/divorced                 | 38 (11%)                          | 130 (17%)                    |
| **Previous pregnancies\textsuperscript{1} (n=903)**         |                                   |                              |
| 1                                                          | 95 (32%)                          | 287 (47%)                    |
| 2                                                          | 87 (29%)                          | 147 (24%)                    |
| 3 or more                                                   | 116 (39%)                         | 171 (28%)                    |
| **Age at leaving full-time education (n=653)**              |                                   |                              |
| ≤16 years                                                   | 32 (14%)                          | 71 (16%)                     |
| 17–18 years                                                 | 44 (20%)                          | 84 (19%)                     |
| ≥19 years                                                   | 146 (66%)                         | 276 (64%)                    |
| **History of injecting drug use (n=1120)**                  |                                   |                              |
| No                                                         | 247 (73%)                         | 616 (79%)                    |
| Yes                                                        | 90 (27%)                          | 167 (21%)                    |
| **Alcohol use postnatally (n=1104)**                       |                                   |                              |
| No                                                         | 268 (81%)                         | 603 (78%)                    |
| Yes                                                        | 63 (19%)                          | 170 (22%)                    |
| **History of smoking (n=1114)**                             |                                   |                              |
| No                                                         | 98 (29%)                          | 238 (31%)                    |
| Yes                                                        | 236 (71%)                         | 542 (69%)                    |
| **Current smoking (n=1111)**                                |                                   |                              |
| No                                                         | 153 (46%)                         | 389 (50%)                    |
| Yes                                                        | 181 (54%)                         | 388 (50%)                    |
| **Disclosure of HIV status to anyone (n=1120)**             |                                   |                              |
| No                                                         | 15 (4%)                           | 42 (5%)                      |
| Yes                                                        | 322 (96%)                         | 741 (95%)                    |
| **Disclosure of HIV status to family/friends (n=1120)**     |                                   |                              |
| No                                                         | 107 (32%)                         | 293 (37%)                    |
| Yes                                                        | 230 (68%)                         | 490 (63%)                    |
| **Disclosure of HIV status to partner (n=1120)**            |                                   |                              |
| No                                                         | 67 (20%)                          | 189 (24%)                    |
| Yes                                                        | 270 (80%)                         | 594 (76%)                    |
| **WHO stage (n=1109)**                                     |                                   |                              |
| 1–2                                                        | 255 (76%)                         | 657 (85%)                    |
| 3–4                                                        | 82 (24%)                          | 115 (15%)                    |
| **CD4 count (n=959)**                                      |                                   |                              |
| ≤ 200 cells/mm\textsuperscript{3}                         | 22 (7%)                           | 63 (10%)                     |
| 201–350 cells/mm\textsuperscript{3}                       | 56 (18%)                          | 114 (18%)                    |
| > 350 cells/mm\textsuperscript{3}                         | 234 (75%)                         | 470 (73%)                    |
| Median                                                     | 468 cells/mm\textsuperscript{3}   | 456 cells/mm\textsuperscript{3} |
| **Taking ART postnatally (n=1114)**                        |                                   |                              |
| No                                                         | 262 (78%)                         | 643 (82%)                    |
| Yes                                                        | 72 (22%)                          | 137 (18%)                    |
| **Any OC\textsuperscript{1} use reported postnatally (n=1120)** |                         |                              |
| No                                                         | 291 (86%)                         | 715 (91%)                    |
| Yes                                                        | 46 (14%)                          | 68 (9%)                      |
simplex virus 2 (HSV-2) infection, chlamydia infection and CD4
count) [31]. Other variables were considered for inclusion in the
multivariable model only if significant in univariable analyses
($p<0.10$).

Sexually transmitted infections (STIs) and genital infections
(vulvo-vaginal candida and BV) were not considered in the
analyses of factors associated with having a cervical screening test
reported due to problems with interpretation of potential
associations, particularly in terms of direction of effect, e.g. cervical
screening could have prompted investigation for infections and vice
versa. However, associations between STIs/genital
infections and cervical abnormality were explored as some
infections are known risk factors for invasive cervical cancer.

At the time of analysis, only 21% (233/1120) of women had
follow-up data available reflecting the recent establishment of this
cohort, long follow-up intervals among women not receiving ART,
and also possible loss to follow-up. As women with follow-up were
not representative of the cohort as a whole with respect to health-
seeking behaviours, follow-up data were omitted from analyses.

Data were managed in an Access 2003 database (Microsoft
Corps, Redmond, WA, USA) and statistical analyses were
performed in Stata version 11.0 (StataCorp LP, College Station,
Texas, USA).

**Results**

A total of 1120 women were enrolled at Odessa, Kiev and
Donetsk centres from December 2007 to March 2011, at a median
of 10 months postpartum (83% (924/1120) at ≥12 weeks
postpartum). Median age at enrolment was 27.3 years (IQR
24.2, 30.6). HIV diagnosis occurred a median of 1.5 years (IQR
1.0, 2.5) prior to enrolment. For two-thirds (665/971), this was
during their most recent pregnancy and for one third (306/971)
prior to conception. Women diagnosed <6 months before
enrolment (and therefore within the interval for cervical screening
according to Ukraine policy) accounted for 7% (69/970).

Almost all (971/972) women were born in Ukraine and 23%
(257/1120) had a history of IDU, about a third (89/255) of whom
had a sex partner who also injected drugs. Of those without an
IDU history, 12% (88/716) reported a sex partner who injected
drugs. Overall a third (257/872) were seropositive for hepatitis C
virus (HCV), 55% (163/299) of whom had an IDU history. A
date (257/1120) of women tested for chlamydia, 25% (215/851) were positive, of whom 78% (164/211) had at least one
STI in addition to chlamydia and HIV (mostly
HSV-2). Overall, 18% (197/1109) had advanced or severe
symptomatic HIV disease (WHO stages 3 or 4), and 27% (255/
959) had a CD4 count ≥350 cells/mm³. Almost half (44%, 422/
949) were multiparous at enrolment. Of those who reported being
sexually active postnatally, 88% (699/794) reported use of
condoms, most (83%, 581/699) as their only method of
contraception.

Cohort characteristics by cervical screening test receipt are
shown in Table 1, and prevalence of coinfections diagnosed during
pregnancy or postnatally in Table 2. Just under a third of women
(337/1120) had a cervical screening test reported at enrolment.
Over half of those with date of cervical screening test reported
(180/310) had received their most recent test postnatally (median
28 weeks after delivery, 24% (74/310) during pregnancy and 18% (56/310) pre-conception.
Most (69%, 232/334) had been tested over six months and
34% (115/334) over one year previously (median 40 weeks prior to
enrolment). Women diagnosed with HIV prior to conception were
more likely than those diagnosed antenatally or intrapartum to
have a screening test reported at enrolment (44% (136/306) versus
26% (176/665), \(\chi^2 = 31.06\, p<0.01\)). Of the 783 women with no
test at baseline, 22% (n = 176) had follow-up data available, of
whom 39% (68/176) had been screened at follow-up.

**Factors Associated with Having a Cervical Screening Test**

Result Reported as Part of HIV Care

There was no significant change over time in the proportion of
women with a screening test reported as part of HIV care at study
enrolment (30% overall, \(p = 0.87\)). In univariable analyses, age,
maternal status, number of previous pregnancies, IDU history,
WHO clinical stage, timing of HIV diagnosis, affordability of
contraception and centre were significantly associated with having
a screening test at the HIV/AIDS Centre (Table 3). HCV
seropositivity and IDU history were both associated with report of
a screening test in univariable analysis (\(\chi^2 = 9.69, \, p<0.01\) and
\(\chi^2 = 3.85, \, p = 0.05\) respectively), but not on adjusting for year and
centre \(p = 0.44\) and \(p = 0.48\) respectively), and were therefore
excluded from the multivariable model. HCV seropositivity is
omitted from Table 3 due to its overlap with IDU history. Other
factors that were not associated with having a test reported were
smoking (current or history), current alcohol use, disclosure of
HIV status to a partner, postnatal ART receipt and CD4 count.

In the multivariable model, there were significant differences in
reporting of cervical screening tests by centre (Wald test \(p<0.01\)
(Table 3), and women were twice as likely to have a test reported if
diagnosed prior to their most recent pregnancy rather during the
3rd trimester or intrapartum. Women with one previous pregnancy
\(vs \geq 2\) were less likely to have a test reported \(p = 0.05\).

In order to investigate factors associated with being screened at
the HIV/AIDS Centre among women with longest exposure to
HIV care, a sub-analysis was conducted limited to the 306 women
diagnosed with HIV before their most recent pregnancy. In this
group, 44% (136/306) of whom had a cervical screening test result
reported at enrolment, age, marital status, self-reported afford-
ability of contraception, HIV disclosure and centre were

---

| Table 1. Cont. | Test reported at enrolment \((n = 337)\) | No test at enrolment \((n = 783)\) |
|---------------|---------------------------------|---------------------------------|
| Can afford family planning (self-report) \((n = 1089)\) | | |
| No            | 40 (12%) | 179 (24%) |
| Yes           | 292 (88%) | 578 (76%) |

1Includes non-cohabiting partnerships;
2Previous pregnancies include still births, live births, miscarriages and terminations. OC, oral hormonal contraceptive.

doi:10.1371/journal.pone.0034706.t001

---

Factors Associated with Having a Cervical Screening Test

Result Reported as Part of HIV Care

There was no significant change over time in the proportion of
women with a screening test reported as part of HIV care at study
enrolment (30% overall, \(p = 0.87\)). In univariable analyses, age,
maternal status, number of previous pregnancies, IDU history,
WHO clinical stage, timing of HIV diagnosis, affordability of
contraception and centre were significantly associated with having
a screening test at the HIV/AIDS Centre (Table 3). HCV
seropositivity and IDU history were both associated with report of
a screening test in univariable analysis (\(\chi^2 = 9.69, \, p<0.01\) and
\(\chi^2 = 3.85, \, p = 0.05\) respectively), but not on adjusting for year and
centre \(p = 0.44\) and \(p = 0.48\) respectively), and were therefore
excluded from the multivariable model. HCV seropositivity is
omitted from Table 3 due to its overlap with IDU history. Other
factors that were not associated with having a test reported were
smoking (current or history), current alcohol use, disclosure of
HIV status to a partner, postnatal ART receipt and CD4 count.

In the multivariable model, there were significant differences in
reporting of cervical screening tests by centre (Wald test \(p<0.01\)
(Table 3), and women were twice as likely to have a test reported if
diagnosed prior to their most recent pregnancy rather during the
3rd trimester or intrapartum. Women with one previous pregnancy
\(vs \geq 2\) were less likely to have a test reported \(p = 0.05\).

In order to investigate factors associated with being screened at
the HIV/AIDS Centre among women with longest exposure to
HIV care, a sub-analysis was conducted limited to the 306 women
diagnosed with HIV before their most recent pregnancy. In this
group, 44% (136/306) of whom had a cervical screening test result
reported at enrolment, age, marital status, self-reported afford-
ability of contraception, HIV disclosure and centre were
### Table 2. Coinfections by cervical screening test report at enrolment.

| Coinfection                      | Test reported at enrolment (n = 337) | No test at enrolment (n = 783) |
|----------------------------------|--------------------------------------|--------------------------------|
| Chlamydia (n = 851)              | 71 (25%)                             | 144 (25%)                      |
| Syphilis (n = 907)               | 13 (4%)                              | 17 (3%)                        |
| Trichomonas vaginalis (n = 645)  | 19 (6%)                              | 52 (15%)                       |
| HSV-2 antibodies (n = 806)       | 156 (55%)                            | 255 (49%)                      |
| Vulvo-vaginal candida (n = 739)  | 134 (43%)                            | 232 (54%)                      |
| Bacterial vaginosis (n = 731)    | 67 (22%)                             | 59 (14%)                       |
| Hepatitis C seropositive (n = 872)| 120 (41%)                            | 179 (31%)                      |
| Hepatitis B surface antigen positive (n = 1002) | 23 (7%)                             | 61 (9%)                        |

### Table 3. Factors associated with having a cervical screening test reported at study enrolment.

| Factor                          | Proportion (n with test reported at enrolment) | Crude PR (95% CI) | p-value | Adjusted PR – multivariable model (95% CI) | p-value |
|---------------------------------|-----------------------------------------------|-------------------|---------|-------------------------------------------|---------|
| **Age at enrolment**            |                                               |                   |         |                                           |         |
| 16–23 years                     | 21% (55/265)                                  | 1.00              | 1.00    |                                           | 1.00    |
| 24–26 years                     | 31% (78/255)                                  | 1.25 (0.91,1.73)  | 0.17    | 1.07 (0.78,1.47)                          | 0.68    |
| 27–30 years                     | 33% (111/339)                                 | 1.49 (1.11,2.00)  | < 0.01  | 1.13 (0.84,1.51)                          | 0.42    |
| ≥31 years                       | 36% (92/257)                                  | 1.55 (1.14,2.10)  | < 0.01  | 1.24 (0.90,1.69)                          | 0.18    |
| **Marital status**              |                                               |                   |         |                                           |         |
| Married                         | 35% (225/637)                                 | 1.00              | 1.00    |                                           | 1.00    |
| Cohabitating                    | 24% (73/308)                                  | 0.72 (0.56,0.92)  | < 0.01  | 0.81 (0.63,1.04)                          | 0.10    |
| Single/widowed/divorced         | 23% (38/168)                                  | 0.68 (0.50,0.93)  | 0.02    | 0.84 (0.61,1.16)                          | 0.29    |
| **Previous pregnancies at enrolment** |                                              |                   |         |                                           |         |
| ≥2                              | 39% (203/521)                                 | 1.00              | 1.00    |                                           | 1.00    |
| 1                               | 25% (95/382)                                  | 0.64 (0.52,0.79)  | < 0.01  | 0.80 (0.65,1.00)                          | 0.05    |
| **History of IDU**              |                                               |                   |         |                                           |         |
| No                              | 29% (247/863)                                 | 1.00              |         |                                           |         |
| Yes                             | 35% (90/257)                                  | 1.24 (1.01,1.52)  | 0.04    |                                           |         |
| **WHO clinical stage**          |                                               |                   |         |                                           |         |
| 1–2                             | 28% (255/912)                                 | 1.00              | 1.00    |                                           | 1.00    |
| 3–4                             | 42% (82/197)                                  | 1.37 (1.12,1.68)  | < 0.01  | 1.07 (0.87,1.32)                          | 0.51    |
| **Timing of HIV diagnosis**     |                                               |                   |         |                                           |         |
| Prior to conception             | 44% (136/306)                                 | 1.00              | 1.00    |                                           | 1.00    |
| 1st/2nd trimesters              | 28% (155/545)                                 | 0.60 (0.50,0.73)  | < 0.01  | 0.62 (0.51,0.75)                          | < 0.01  |
| 3rd trimester/intrapartum       | 18% (21/120)                                  | 0.41 (0.27,0.61)  | < 0.01  | 0.42 (0.28,0.63)                          | < 0.01  |
| **Affordability of contraception** |                                              |                   |         |                                           |         |
| Can afford                      | 34% (292/870)                                 | 1.00              | 1.00    |                                           | 1.00    |
| Can’t afford                    | 18% (40/219)                                  | 0.62 (0.45,0.85)  | < 0.01  | 0.76 (0.54,1.07)                          | 0.12    |
| **Year of enrolment**           |                                               |                   |         |                                           |         |
| 2007/08                         | 30% (101/339)                                 | 1.00              | 1.00    |                                           | 1.00    |
| 2009                            | 31% (135/435)                                 | 1.05 (0.84,1.31)  | 0.67    | 0.96 (0.76,1.20)                          | 0.71    |
| 2010/11                         | 29% (101/344)                                 | 1.18 (0.93,1.50)  | 0.17    | 0.97 (0.76,1.23)                          | 0.80    |
| **Centre of enrolment**         |                                               |                   |         |                                           |         |
| Odessa                          | 26% (111/419)                                 | 1.00              | 1.00    |                                           | 1.00    |
| Kiev                            | 39% (207/528)                                 | 1.26 (1.03,1.55)  | 0.03    | 1.32 (0.07,1.63)                          | < 0.01  |
| Donetsk                         | 11% (19/173)                                  | 0.42 (0.25,0.71)  | < 0.01  | 0.49 (0.29,0.82)                          | < 0.01  |

*Limited to 870 women included in the multivariable model.

Note: Adjusted PRs were calculated using a logistic regression model with the following covariates: age, marital status, previous pregnancies, history of IDU, WHO clinical stage, timing of HIV diagnosis, affordability of contraception, year of enrolment, and centre of enrolment. The model was adjusted for potential confounders and interaction terms.

**References**: Table 2 and Table 3 are from the study titled “Cervical Screening within HIV Care in Ukraine” published in PLoS ONE. The full study can be accessed via the doi:10.1371/journal.pone.0034706.t002 and doi:10.1371/journal.pone.0034706.t003.
significantly associated with reporting of a test result in univariable analyses (Table 4). In the multivariable analyses adjusting for year, centre and affordability of contraception, women leaving full-time education at ≥16 (vs ≥19 years) and who were cohabiting (vs married) were less likely to have a test reported, although the latter was not statistically significant (p = 0.06) (Table 4). The four-category age variable did not significantly contribute to fit of the model when adjusting for year and centre (Wald test p = 0.14), however women ≥27 years were significantly more likely to have a test reported than those <27 years when a binary variable was used (APR 1.57, 95% CI 1.11–2.00 adjusting for marital status, education, affordability of contraception, year and centre, p = 0.01).

Although not considered in Poisson regression analyses for reasons specified in the methods, BV was more common among women with a cervical screening test result reported than among those without (22% (67/311) vs 14% (59/420) respectively, \( \chi^2 = 7.04, \ p<0.01 \)). Women with a cervical screening test reported were also more likely to have been tested for BV (92%, 311/337 vs 54% of those without a screening test, 420/783, \( \chi^2 = 155.21, \ p<0.01 \)) and HSV-2 antibodies (85% (285/337) vs. 67% (521/783) of those without a screening test, \( \chi^2 = 37.96, \ p<0.01 \)).

### Cervical Abnormalities

At enrolment, among the 30% with a screening test result reported, prevalence of cervical abnormalities at the most recent test was 21% (68/325) overall (17% (n = 54) LSIL and 4% (n = 14) HSIL). Results were not available for 4% (12/337) of those tested, presumably because the sample was inadequate. In total, 38% (123/325) of women with a screening test result reported at enrolment had the test conducted on the same day as a positive sample was taken or diagnosis made for at least one of: chlamydia, gonorrhoea, syphilis, HSV-2, candida, TV or BV. Among the 68

### Table 4. Factors associated with having a cervical screening test reported at study enrolment, among women diagnosed with HIV prior to most recent pregnancy.

|                              | Proportion (n) with test reported at enrolment | Crude PR n = 207 \( ^1 \) | p-value | Adjusted PR – multivariable model (95% CI) n = 207 \( ^1 \) | p-value |
|------------------------------|-----------------------------------------------|-----------------------------|---------|-------------------------------------------------|---------|
| Age at enrolment              |                                              |                             |         |                                                 |         |
| 16–23 years                   | 27% (12/44)                                   | 1.00                        |         |                                                 |         |
| 24–26 years                   | 39% (24/62)                                   | 1.22 (0.62,2.41)            | 0.56    |                                                 |         |
| 27–30 years                   | 51% (56/110)                                  | 1.77 (0.98,3.21)            | 0.06    |                                                 |         |
| ≥31 years                     | 49% (44/89)                                   | 1.93 (1.06,3.50)            | 0.03    |                                                 |         |
| Marital status                |                                              |                             |         |                                                 |         |
| Married                       | 55% (99/180)                                  | 1.00                        |         |                                                 |         |
| Cohabiting                    | 30% (24/80)                                   | 0.41 (0.23,0.73)            | <0.01   | 0.58 (0.32,1.03)                                | 0.06    |
| Single/widowed/divorced       | 27% (12/44)                                   | 0.55 (0.31,0.97)            | 0.04    | 0.74 (0.42,1.31)                                | 0.30    |
| Age at leaving full-time education \( ^1 \) | | | | | |
| ≥19 years                     | 50% (60/121)                                  | 1.00                        |         |                                                 |         |
| 17–18 years                   | 46% (21/46)                                   | 0.94 (0.65,1.35)            | 0.75    | 0.79 (0.56,1.13)                                | 0.20    |
| ≥16 years                     | 36% (17/47)                                   | 0.73 (0.48,1.11)            | 0.15    | 0.66 (0.44,1.01)                                | 0.05    |
| Self-reported affordability of contraception | | | | | |
| Can afford                    | 51% (114/223)                                 | 1.00                        |         |                                                 |         |
| Can’t afford                  | 25% (19/75)                                   | 0.43 (0.25,0.74)            | <0.01   | 0.79 (0.44,1.43)                                | 0.44    |
| HIV status disclosure to family or friends | | | | | |
| Yes                           | 51% (95/188)                                  | 1.00                        |         |                                                 |         |
| No                            | 35% (41/118)                                  | 0.61 (0.42,0.89)            | 0.01    |                                                 |         |
| WHO stage                     |                                              |                             |         |                                                 |         |
| 1–2                           | 41% (82/202)                                  | 1.00                        |         |                                                 |         |
| 3–4                           | 53% (54/101)                                  | 1.32 (0.99,1.77)            | 0.06    |                                                 |         |
| Year of enrolment             |                                              |                             |         |                                                 |         |
| 2007/08                       | 38% (36/95)                                   | 1.00                        |         |                                                 |         |
| 2009                          | 45% (44/98)                                   | 1.08 (0.72,1.60)            | 0.72    | 0.85 (0.58,1.24)                                | 0.39    |
| 2010/11                       | 50% (56/112)                                  | 1.33 (0.91,1.93)            | 0.14    | 0.91 (0.61,1.36)                                | 0.66    |
| Centre of enrolment           |                                              |                             |         |                                                 |         |
| Odessa                        | 48% (49/102)                                  | 1.00                        |         |                                                 |         |
| Kiev                          | 56% (78/139)                                  | 1.27 (0.87,1.85)            | 0.22    | 1.11 (0.73,1.69)                                | 0.63    |
| Donetsk                       | 14% (9/65)                                    | 0.39 (0.19,0.79)            | 0.01    | 0.38 (0.18,0.80)                                | 0.01    |

\( ^1 \)Limited to the 207 women included in the multivariable model.  
\( ^2 \)Significant on adjusting for year and centre (LRT p = 0.01) and thus included in the multivariable model, as specified in the methods.

doi:10.1371/journal.pone.0034706.t004
women who only had a test reported at follow-up, prevalence of cervical abnormalities was 31% (21/68).

In crude analyses, women with BV infection were more likely to have a diagnosis of LSIL or HSIL, as were those with two or more previous pregnancies and those who were HSV-2 seropositive (Table 5). No other factors were significantly associated with abnormal findings. In the multivariable model, HSV-2 seropositivity was associated with an 83% increased risk of an abnormal finding and BV diagnosed antenatally or postnatally with over a three-fold increased risk (Table 5).

**Discussion**

At enrolment in this postnatal cohort, only 30% of women had a cervical screening test reported as part of HIV care, a third of whom had been screened more than a year previously. Women diagnosed with HIV prior to rather than during their most recent pregnancy, and therefore with more opportunity to receive HIV care, were more likely to have a cervical screening test reported at enrolment, as were those with more previous pregnancies. A fifth of those screened had a finding of LSIL or HSIL.

In this study, we could only assess the coverage of cervical screening carried out as part of HIV care; women may have accessed screening through contraceptive, sexual health or other services. Screening is recommended six-monthly for the general population, but it is unclear whether this policy is followed in practice - in the 2003 World Health Survey 66% of 1361 women reported being screened in the last three years [22], but there were no data on screening frequency, or laboratory or clinical data, with which to validate self-reports. In addition to more regular screening, HIV-positive women may also benefit from more intensive follow-up following a mild abnormal smear, a lower threshold for referral to colposcopy (especially if severely immunosuppressed) and more intensive surveillance immediately following HIV diagnosis compared with the standard of care [17,18]. However, this can only be offered if the healthcare

---

**Table 5. Factors associated with an abnormal finding (LSIL or HSIL) on cervical screening, among women with a test reported at study enrolment.**

|                              | Proportion (n) with abnormal result | Crude PR (95% CI) | p-value | Adjusted PR† (95% CI) | p-value |
|------------------------------|------------------------------------|-------------------|---------|-----------------------|---------|
| **Age at enrolment**         |                                    |                   |         |                       |         |
| 16–23 years                  | 23% (15/65)                        | 1.00              | 1.00    |                       |         |
| 24–26 years                  | 23% (18/77)                        | 1.60 (0.55–4.68)  | 0.39    | 1.52 (0.57–4.04)      | 0.41    |
| 27–30 years                  | 24% (21/89)                        | 1.97 (0.72–5.40)  | 0.19    | 1.72 (0.69–4.31)      | 0.24    |
| ≥31 years                    | 20% (14/69)                        | 1.81 (0.65–5.05)  | 0.26    | 1.42 (0.56–3.60)      | 0.46    |
| **Previous pregnancies at enrolment** |                          |                   |         |                       |         |
| ≥2                           | 26% (51/195)                       | 1.00              | 1.00    |                       |         |
| 1                            | 15% (14/92)                        | 0.44 (0.21–0.93)  | 0.03    | 0.56 (0.26–1.22)      | 0.15    |
| **CD4 count**                |                                    |                   |         |                       |         |
| >350 cells/mm³               | 22% (50/228)                       | 1.00              | 1.00    |                       |         |
| 201–350 cells/mm³            | 21% (11/53)                        | 1.21 (0.65–2.27)  | 0.55    | 1.36 (0.74–2.49)      | 0.33    |
| ≤200 cells/mm³               | 25% (5/20)                         | 1.57 (0.65–3.77)  | 0.31    | 2.07 (0.93–4.57)      | 0.07    |
| **Currently smoking**        |                                    |                   |         |                       |         |
| No                           | 25% (38/151)                       | 1.00              |         |                       |         |
| Yes                          | 19% (33/171)                       | 0.99 (0.59–1.67)  | 0.09    | 0.78 (0.49–1.26)      | 0.31    |
| **Oral contraceptive use postnatally (any)** |                          |                   |         |                       |         |
| No                           | 22% (61/279)                       | 1.00              |         |                       |         |
| Yes                          | 24% (11/46)                        | 0.94 (0.46–1.93)  | 0.86    | 0.95 (0.48–1.88)      | 0.88    |
| **HSV-2**                    |                                    |                   |         |                       |         |
| No                           | 18% (22/125)                       | 1.00              |         |                       |         |
| Yes                          | 27% (40/150)                       | 1.73 (1.00–3.00)  | 0.05    | 1.83 (1.07–3.11)      | 0.03    |
| **Chlamydia**                |                                    |                   |         |                       |         |
| No                           | 20% (41/205)                       | 1.00              |         |                       |         |
| Yes                          | 25% (17/68)                        | 1.32 (0.75–2.32)  | 0.33    | 0.79 (0.46–1.36)      | 0.40    |
| **Bacterial vaginosis**      |                                    |                   |         |                       |         |
| No                           | 17% (40/236)                       | 1.00              |         |                       |         |
| Yes                          | 39% (25/64)                        | 3.36 (2.07–5.45)  | <0.01   | 3.49 (2.11–5.76)      | <0.01   |
| **Trichomonas vaginalis**    |                                    |                   |         |                       |         |
| No                           | 19% (52/269)                       | 1.00              |         |                       |         |
| Yes                          | 44% (8/18)                         | 1.80 (0.76–4.24)  | 0.18    |                       |         |

†Limited to 213 women included in the multivariable model.

Adjusted a priori for age, previous pregnancies, CD4 count, current smoking, oral contraceptive use, HSV-2 and chlamydia and additionally for BV. doi:10.1371/journal.pone.0034706.t005
Women in poorer socioeconomic groups are less likely to be screened for cervical abnormalities in the US [53], and in Ukraine, where World Household Survey data showed coverage with three-yearly screening of 87% in the top and 60% in the bottom wealth quintiles [23]. HIV-positive women may be socially disadvantaged due to their poor health, discriminatory employment practices and coexisting behaviours (e.g. IDU). In our study, a fifth reported being unable to afford contraception and a third had not disclosed their HIV status to a parent, family member or friend, indicating both economic and social marginalisation. Among those diagnosed prior to conception, women with fewest years of education were least likely to have been screened. An organised screening programme could improve awareness and uptake among the most marginalised women. At an HIV clinic in the United Kingdom, a higher uptake of cervical screening was found among women on HAART compared with those not yet on treatment, probably due to their on-going engagement with HIV care [56]. Regular invitations to attend the HIV/AIDS Centre for screening could help prevent postpartum loss to follow-up among HIV-positive women not on ART. As national policy, organised screening programmes delivered as part of HIV care could also lessen the regional disparities in screening coverage.

In Eastern Europe 70% of cervical cancer cases are attributed to vaccine-preventable HPV types 16 and 18 [22,57], but HPV vaccination programmes have yet to be introduced in Ukraine [22]. The safety and efficacy of HPV vaccination in immunocompromised populations have not yet been established [37]. Although an important future intervention, HPV vaccination will not obviate the need for an organised cervical screening programme in Ukraine.

Limitations

Lack of data on cervical HPV infection or sexual risk behaviours precluded more detailed exploration of the association between BV and LSIL/HSIL. False positives or negatives cannot be ruled out, particularly as a quarter of the samples were taken in pregnancy, 10% at <12 weeks postpartum and 38% on the same day as a positive sample for a genital infection [20]. We are not able to comment on sensitivity and specificity of cytologic screening in this population, as colposcopy and histology take place at referral hospitals and data are not routinely shared with the HIV/AIDS Centre. Because women with a screening test had a higher prevalence of BV than those without, the observed prevalence of cervical abnormalities in this study could be an overestimate. Furthermore, since cervical screening test results were only available for 30% of women, selection bias in the association between BV and cervical abnormalities (e.g. due to sexual risk-taking behaviour) cannot be ruled out. Local differences exist in provision of cervical screening services both within and outside of HIV care, and our results may therefore not be generalizable to other areas in Ukraine. Finally, coverage of cervical screening as part of HIV care may be higher in this cohort than in the wider population of HIV-positive women in Ukraine, as all women in the cohort were in contact with HIV healthcare services.

In conclusion, cervical screening coverage of this high risk population as part of HIV care is low. An organised programme where women are invited to attend the HIV/AIDS Centre for cervical screening could increase coverage, particularly among marginalised women. BV testing and treatment could potentially reduce vulnerability to cervical abnormalities.
Acknowledgments

The Ukraine European Collaborative Study Group consists of the following members who have contributed to this study: Prof ML Newell (UCL Institute of Child Health, UK), Dr. S. Servetsky, Dr. R.Teretsenko (Odessa Regional Centre for HIV/AIDS, Ukraine), Dr. M. Grazhdanov, Dr. Kulakovsky (Donetsk Regional Centre for HIV/AIDS, Ukraine), Dr. I. Achamovska, Dr. O. Vurchenko (Kiev City Centre for HIV/AIDS, Ukraine), Dr. L. Ostrovskaya, Dr. I. Korcherynia (Mikolajev Regional Centre for HIV/AIDS, Ukraine), Dr. L. Kvasha, Dr. G. Kruglenko (Kriviy Rig City Center for HIV/AIDS, Ukraine).

Research Ethics Approval

The Women’s Study is nested within the European Collaborative Study. Both these studies use anonymised coded data (the “key” to this code (i.e. study identifier) is held by the woman’s clinician). The European Collaborative Study has ethical approval from the Great Ormond Street Hospital for Children NHS Trust/Institute of Child Health Research Ethics Committee. This includes approval of the procedure of obtaining verbal and not written consent from participating women, given the anonymous nature of the study. Furthermore, within the Women’s Study protocol, women are required to complete an anonymised questionnaire at enrolment. The return of this questionnaire by the woman is taken as documentation and evidence of her consent to participate. There is no formal ethics review process in Ukraine for studies conducted within the public healthcare system. Local institutional review board approval was therefore granted by clinic directors on an individual clinic basis at each participating site (Odessa Regional Centre for HIV/ AIDS, Kiev City Centre for HIV/AIDS, Donetsk Regional Centre for HIV/AIDS, Kriviy Rig City Centre for HIV/AIDS and Mykolajev Regional Centre for HIV/AIDS).

Author Contributions

Conceived and designed the experiments: CT RM. Performed the experiments: IS RT IA EK LO LC. Analyzed the data: HB CT CLT. Contributed reagents/materials/analysis tools: MCB. Wrote the paper: HB CT CLT. Revised the manuscript for intellectual content: IS RM RT IA EK LO LC MCB.

References

1. Kruglov YV, Kobyluchya YV, Sytyk T, Varetska O, Shakarishvili A, et al. (2008) The most severe HIV epidemic in Europe: Ukraine’s national HIV prevalence estimates for 2007. Sexually Transmitted Infections 84: 137–41.
2. Ministry of Health of Ukraine (2010) Ukraine: National Report on Monitoring Progress Towards the UNAIDS Declaration of Commitment on HIV/AIDS. January 2008–December 2009.
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2010) Global report: UNAIDS report on the global AIDS epidemic 2010.
4. Minkoff H, Feldman J, Behrns J, Landsman S, Burk R (1995). A longitudinal study of human papillomavirus carriage in human immunodeficiency virus-infected and human immunodeficiency virus-uninfected women. Am J Obstet Gynecol 176: 902–906.
5. Sim XW, Kushi L, Ellerbrock TV, Chaisson MA, Bush TJ, et al. (1997) Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337: 1343–1349.
6. Phealan DF, Gange SJ, Adelsch Grant L, Mehra SH, Kirk GD, et al. (2009) Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected Injection Drug Using Women. Sex Transm Dis 36: 149–156.
7. Kojie EM, Cu-Uvin S (2007) Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 19: 464–469.
8. Franceschi S, Ronco G (2010) The prevention of cervical cancer in HIV-infected women. AIDS 24: 2579–2585.
9. Maiman M (1999) Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr 23: 43–49.
10. Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, et al. (1994) Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 57: 836–840.
11. Clifford GM, Pope-Elpek J, Rickenbach M, Dal ML, Kreier O, et al. (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97: 432–434.
12. Frisch M, Bigger RJ, Goedert JJ (2000) Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92: 1500–1510.
13. Gustafsson L, Porten J, Zack M, Adams HO (1997) International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8: 753–763.
14. Petz J, Gilham C, Fletcher O, Matheses FE (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364: 229–236.
15. NHS Cancer Screening Programmes (2010) Colposcopy and Programme Management - Guidelines for the NHS Cervical Screening Programme, 2nd Edition 2010.
16. Sawaya GF (2009) Cervical-cancer screening–new guidelines and the balance between benefits and harms. N Engl J Med 361: 2503–2505.
17. Centers for Disease Control and Prevention (2009) Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents - Recommendations from CDC, the Nation Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 58, No. RR-4.
18. El-Guebaly, Lamber C, Mackle N, Nandwani R, Brown A, et al. (2008) British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med 9: 681–720.
19. Wright TC, Jr., Masad LS, Dunton CJ, Spaitzer M, Wilkinson EJ, et al. (2007) 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol 197: 340–345.
20. Flanagely G (2010) The management of women with abnormal cervical cytology in pregnancy. Best Pract Res Clin Obstet Gynaecol 24: 51–60.
21. Ministry of Health of Ukraine (2002) On Improvement of Ambulatory Obstetric and Gynecological Help in Ukraine. Order 503.
22. WHO/ICO Information Centre on HPV and Cervical Cancer (2010) Human Papillomavirus and Related Cancers in Ukraine. Summary Report 2010. 3rd Edition.
23. Gakidou E, Nordhagen S, Obermeyer Z (2000) Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 5: e132.
24. Castellsagué X, de Sanjose S, Aguado T, Louie KS, Bruni L, et al. (2007) HPV and Cervical Cancer in the World. 2007 Report.
25. Saxon J, Maluya R, Semenouk I, Piñolbento K, Tereshokov R, et al. (2010) Previous reproductive history and post-natal family planning among HIV-infected women in Ukraine. Human Reproduction 25: 2366–2373.
26. European Collaborative Study, Boer K, England K, Godfried MH, Thorne C (2010) Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Medicine 11: 368–378.
27. Thorne C, Semenouk I, Piñolbento K, Maluya R; Ukrainian European Collaborative Study Group (2009) Progress in prevention of mother-to-child transmission of HIV infection in Ukraine: results from a birth cohort study. BMC Infectious Diseases 9.
28. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, et al. (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114–2119.
29. World Health Organisation (2006) WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Available: http://www.who.int/hiv/pub/guidelines/WHO HIV Staging.pdf. Accessed 2011 Sept.
30. Barros AJ, Hirakata VN (2003) Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 3: 21.
31. Mutoz N, Castellsague X, de Gonzalez AB, Gissmann L, et al. (2006) Chapter 1: HPV in the etiology of human cancer. Vaccine 24 Suppl 3: S83–1 S810.
32. Maiman M, Fruchter RG, Sells A, Feldman J, Chen P, et al. (1998) Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 68: 233–239.
33. Kitchener H, Nelson L, Adams J, Meshier D, Sasieni P, et al. (2007) Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 124: 2850–2856.
34. Mbizo EM, Msuya SE, Stray-Pedersen B, Chirenje MZ, Hussain A (2005) Cervical dyskaryosis among women with and without HIV: prevalence and risk factors. Int J STD AIDS 16: 789–793.
35. Massad LS, Seaberg EC, Venzke DH, Hessol NA, Melnick S, et al. (2004) Low incidence of invasive cervical cancer among HIV-infected US women in a prevention program. AIDS 18: 109–113.
36. Del MA, Bernerolle R, Franzetti M, Castelan A, Torrisi A, et al. (2004) Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 38: 737–742.
37. Heid I (2009) Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 4: 68–73.
38. Minkoff H, Zhong Y, Burke RD, Palefsky JM, Xue X, et al. (2010) Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 201: 681–690.

Cervical Screening within HIV Care in Ukraine
39. Ahdieh-Grant L, Li R, Levine AM, Masaud LS, Strickler HD, et al. (2004) Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 96: 1070–1076.
40. Uberti-Foppa C, Ferrari D, Lodini S, Reina S, Ameglio F, et al. (2003) Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. AIDS 17: 2136–2138.
41. Franceschi S, Jaffe H (2007) Cervical cancer screening of women living with HIV infection: a must in the era of antiretroviral therapy. Clin Infect Dis 45: 510–513.
42. Castle PE, Giuliano AR (2003) Chapter 4: Genital tract infections, cervical inflammation, and antioxidants: assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 29–34.
43. Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, et al. (2002) Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 94: 1604–1613.
44. Guijon F, Paraskeva M, Rand F, Heywood E, Brunham R, et al. (1992) Vaginal microbial flora as a cofactor in the pathogenesis of uterine cervical intraepithelial neoplasia. Int J Gynaecol Obstet 37: 185–191.
45. Boyle DC, Barton SE, Uhayakumar S, Hay PE, Pollock JW, et al. (2003) Is bacterial vaginosis associated with cervical intraepithelial neoplasia? Int J Gynecol Cancer 13: 159–163.
46. Peters N, Van Leeuwen AM, Pieters WJ, Hollema H, Quint WG, et al. (1995) Bacterial vaginosis is not important in the etiology of cervical neoplasia: a survey on women with dyskaryotic smears. Sex Transm Dis 22: 296–302.
47. Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, et al. (2001) Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285: 2995–3002.
48. Platz-Christensen J, Sundstrom E, Larsson PG (1994) Bacterial vaginosis and cervical intraepithelial neoplasia. Acta Obstet Gynecol Scand 73: 586–589.
49. Gillet E, Meys JF, Verstraeten H, Boire G, De SP, et al. (2011) Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis 11: 10.
50. Watts DH, Fauzari M, Minkoff H, Hillier SL, Sha B, et al. (2005) Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 191: 1129–1139.
51. King CC, Jamieson DJ, Wiener J, Cu-Uvin S, Klein RS, et al. (2011) Bacterial vaginosis and the natural history of human papillomavirus. Infect Dis Obstet Gynecol 2011: 319460.
52. Leitch H, Bodner-Adler B, Brumback M, Kaidar A, Egarter C, et al. (2003) Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol 189: 139–147.
53. Allworth JE, Peipert JF (2011) Severity of bacterial vaginosis and the risk of sexually transmitted infection. Am J Obstet Gynecol 205: 113.e1–113.e6.
54. Newmann SJ, Garner EO (2005) Social inequities along the cervical cancer continuum: a structured review. Cancer Causes Control 16: 63–70.
55. Shah S, Montgomery H, Smith C, Madge S, Walker P, et al. (2006) Cervical screening in HIV-positive women: characteristics of those who default and attitudes towards screening. HIV Med 7: 46–52.
56. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006) Chapter 3: HPV type distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3: S3–26–S3/34.